Vyome Holdings, Inc. (HIND)
2.21
+0.03
(+1.38%)
USD |
NASDAQ |
Sep 03, 16:00
2.20
-0.01
(-0.45%)
After-Hours: 20:00
Vyome Holdings Research and Development Expense (Annual) : 0.5883M for Dec. 31, 2025
Research and Development Expense (Annual) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | 0.5883M |
| December 31, 2024 | 0.2854M |
| December 31, 2023 | 2.315M |
| December 31, 2022 | 2.537M |
| December 31, 2021 | 2.369M |
| December 31, 2020 | 3.498M |
| Date | Value |
|---|---|
| December 31, 2019 | 6.523M |
| December 31, 2018 | 10.70M |
| December 31, 2017 | 10.65M |
| December 31, 2016 | 9.872M |
| December 31, 2015 | 12.98M |
| December 31, 2014 | 5.767M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Annual) Benchmarks
| Cardiac Biotech Solutions, Inc. | 0.0275M |
| Anika Therapeutics, Inc. | 25.77M |
| Enovis Corp. | 120.33M |
| Edwards Lifesciences Corp. | 1.079B |
| Perspective Therapeutics, Inc. | 70.96M |